CL2014000813A1 - El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras - Google Patents

El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras

Info

Publication number: CL2014000813A1
Authority: CL; Chile
Prior art keywords: anilinopyrimidin; naphthalen; mitogen; pyrazolyl; psoriasis
Prior art date: 2011-10-03

Application number

CL2014000813A

Other languages

English (en)

Inventor

John King-Underwood

Kazuhiro Ito

Catherine Elisabeth Charron

Stuart Thomas Onions

Alistair Ian Longshaw

Rudy Broeckx

Walter Filliers

Alex Copmans

Original Assignee

Respivert Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-03

Filing date

2014-04-02

Publication date

2014-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47018247&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014000813(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-10-03 Priority claimed from EP11183688.8A external-priority patent/EP2578582A1/en

2014-04-02 Application filed by Respivert Ltd filed Critical Respivert Ltd

2014-07-25 Publication of CL2014000813A1 publication Critical patent/CL2014000813A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Virology (AREA)
Oncology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Emergency Medicine (AREA)
Otolaryngology (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Cardiology (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Physical Education & Sports Medicine (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

CL2014000813A 2011-10-03 2014-04-02 El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras CL2014000813A1 (es)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP11183682		2011-10-03
EP11183688.8A EP2578582A1 (en)	2011-10-03	2011-10-03	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
EP12168396		2012-05-16
EP12168395		2012-05-16

Publications (1)

Publication Number	Publication Date
CL2014000813A1 true CL2014000813A1 (es)	2014-07-25

Family

ID=47018247

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014000813A CL2014000813A1 (es)	2011-10-03	2014-04-02	El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras

Country Status (25)

Country	Link
US (5)	US9108950B2 (es)
EP (1)	EP2763984B1 (es)
JP (2)	JP2014528404A (es)
KR (2)	KR102057058B1 (es)
CN (1)	CN103917536B (es)
AU (1)	AU2012320300C1 (es)
BR (1)	BR112014007694B1 (es)
CA (1)	CA2846222C (es)
CL (1)	CL2014000813A1 (es)
CO (1)	CO6910202A2 (es)
EA (1)	EA023650B1 (es)
EC (1)	ECSP14013282A (es)
ES (1)	ES2583853T3 (es)
GT (1)	GT201400054A (es)
IL (1)	IL231025A (es)
MX (1)	MX342168B (es)
MY (1)	MY167798A (es)
NI (1)	NI201400027A (es)
PE (1)	PE20142355A1 (es)
PH (1)	PH12014500547A1 (es)
PL (1)	PL2763984T3 (es)
PT (1)	PT2763984T (es)
SG (1)	SG11201400226UA (es)
WO (1)	WO2013050757A1 (es)
ZA (1)	ZA201403204B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5511680B2 (ja)	2007-12-19	2014-06-04	キャンサー・リサーチ・テクノロジー・リミテッド	ピリド［２，３−ｂ］ピラジン−８−置換化合物及びその使用
NZ601085A (en)	2010-02-01	2015-04-24	Cancer Rec Tech Ltd	1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
EP2763984B1 (en) *	2011-10-03	2016-04-20	Respivert Limited	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en) *	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en) *	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GB201215357D0 (en) *	2012-08-29	2012-10-10	Respivert Ltd	Compounds
WO2014033447A2 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
US20150210722A1 (en)	2012-08-29	2015-07-30	Respivert Limited	Kinase inhibitors
EP2890701B1 (en)	2012-08-29	2017-03-29	Respivert Limited	Kinase inhibitors
WO2014076484A1 (en)	2012-11-16	2014-05-22	Respivert Limited	Kinase inhibitors
US20160016934A1 (en)	2013-03-14	2016-01-21	Respivert Limited	Kinase inhibitors
BR112015024678B1 (pt) *	2013-04-02	2023-02-23	Oxular Acquisitions Limited	Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários
US9771353B2 (en)	2013-04-02	2017-09-26	Topivert Pharma Limited	Kinase inhibitors based upon N-alkyl pyrazoles
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
GB201320732D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Methods of chemical synthesis
JP6514703B2 (ja)	2013-12-20	2019-05-15	トピバートファーマリミテッド	キナーゼインヒビターとして有用な尿素誘導体
TWI664967B (zh) *	2014-02-14	2019-07-11	英商瑞斯比維特有限公司	新穎化合物（一）
MA40775A (fr)	2014-10-01	2017-08-08	Respivert Ltd	Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
CA3015978A1 (en)	2016-04-06	2017-10-12	Topivert Pharma Limited	Kinase inhibitors
EP3558363A1 (en)	2016-12-21	2019-10-30	Amgen Inc.	Anti-tnf alpha antibody formulations
WO2021013712A1 (en)	2019-07-19	2021-01-28	Anagenesis Biotechnologies S.A.S.	Polyaromatic urea derivatives and their use in the treatment of muscle diseases
US11586495B2 (en) *	2020-07-15	2023-02-21	Micron Technology, Inc.	Fuse logic to perform selectively enabled ECC decoding
EP4029501A1 (en)	2021-01-19	2022-07-20	Anagenesis Biotechnologies	Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
EP4452235A1 (en)	2021-12-20	2024-10-30	Pulmatrix Operating Company, Inc.	Dry powder formulations of narrow spectrum kinase inhibitors

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002507968A (ja)	1997-06-19	2002-03-12	デュポンファーマシューティカルズカンパニー	中性のＰ１特異性基を有するＸａ因子阻害剤
US7329670B1 (en)	1997-12-22	2008-02-12	Bayer Pharmaceuticals Corporation	Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
DK1043995T3 (da)	1997-12-22	2007-03-05	Bayer Pharmaceuticals Corp	Inhibering af p38 kinaseaktivitet ved anvendelse af aryl- og heteroaryl-substituerede, heterocykliske urinstoffer
RU2265597C2 (ru)	1997-12-22	2005-12-10	Байер Копэрейшн	Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ ингибирования киназы raf и фармацевтическая композиция
US20080300281A1 (en)	1997-12-22	2008-12-04	Jacques Dumas	Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
UA73492C2 (en)	1999-01-19	2005-08-15		Aromatic heterocyclic compounds as antiinflammatory agents
EP1200411B1 (en)	1999-07-09	2005-12-14	Boehringer Ingelheim Pharmaceuticals Inc.	Process for synthesis of heteroaryl-substituted urea compounds
CA2389360C (en)	1999-11-16	2008-06-03	Steffen Breitfelder	Urea derivatives as anti-inflammatory agents
US6525046B1 (en)	2000-01-18	2003-02-25	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as antiinflammatory agents
US6492529B1 (en)	2000-01-18	2002-12-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Bis pyrazole-1H-pyrazole intermediates and their synthesis
ATE311366T1 (de)	2000-02-29	2005-12-15	Millennium Pharm Inc	Benzamide und ähnliche inhibitoren vom faktor xa
WO2002083628A1 (en)	2001-04-13	2002-10-24	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-disubstituted benzo-fused compounds
JP2004530690A (ja)	2001-05-16	2004-10-07	ベーリンガーインゲルハイムファーマシューティカルズインコーポレイテッド	抗炎症性薬剤として有用なジアリールウレア誘導体
ATE360417T1 (de)	2001-07-11	2007-05-15	Boehringer Ingelheim Pharma	Methode zur behandlung von zytokinvermittelten erkrankungen
SI1478358T1 (sl)	2002-02-11	2013-09-30	Bayer Healthcare Llc	Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20030216396A1 (en)	2002-02-11	2003-11-20	Bayer Corporation	Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
WO2003072569A1 (en) *	2002-02-25	2003-09-04	Boehringer Ingelheim Pharmaceuticals, Inc.	1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
EP1531815B1 (en)	2002-06-27	2014-09-24	Novo Nordisk A/S	Glucokinase activators
US20040110755A1 (en)	2002-08-13	2004-06-10	Boehringer Ingelheim Pharmaceuticals, Inc.	Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
WO2005110994A2 (en)	2004-04-30	2005-11-24	Bayer Pharmaceuticals Corporation	Substituted pyrazolyl urea derivatives useful in the treatment of cancer
HRP20161751T1 (hr)	2004-05-13	2017-04-07	Icos Corporation	Kinazolinoni kao inhibitori humane fosfatidilinozitol 3-kinaze delta
HRP20080608T3 (hr)	2004-08-12	2008-12-31	Pfizer Inc.	Triazolopiridinilsulfanilni derivati kao inhibitori p38 map kinaze
AU2005321946B2 (en)	2004-12-23	2012-08-16	Deciphera Pharmaceuticals, Llc	Enzyme modulators and treatments
GB0500435D0 (en)	2005-01-10	2005-02-16	Novartis Ag	Organic compounds
US7700620B2 (en)	2005-06-27	2010-04-20	Bristol-Myers Squibb Company	C-linked cyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
PE20070640A1 (es)	2005-10-28	2007-08-10	Lilly Co Eli	Compuestos derivados de pirazol-isoquinolina urea como inhibidores de la cinasa p38
CA2909277A1 (en)	2006-04-04	2007-10-11	Kevan M. Shokat	Kinase antagonists
EA200900571A1 (ru)	2006-10-20	2009-12-30	Айкос Корпорейшн	Композиции chk1 ингибиторов
PT2947072T (pt)	2008-03-17	2016-12-06	Ambit Biosciences Corp	1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
PE20110598A1 (es)	2008-10-02	2011-08-31	Respivert Ltd	Inhibidores de las enzimas de proteina cinasa activadas por mitogeno p38
GB0818033D0 (en)	2008-10-02	2008-11-05	Respivert Ltd	Novel compound
MX2011006220A (es)	2008-12-11	2011-06-28	Respivert Ltd	Inhibidores de la proteina cinasa activada por el mitogeno p38.
EP2367823A1 (en)	2008-12-23	2011-09-28	Abbott Laboratories	Anti-viral compounds
MX2011006332A (es)	2008-12-23	2011-06-27	Abbott Lab	Compuestos antivirales.
WO2010072155A1 (zh)	2008-12-26	2010-07-01	复旦大学	一种嘧啶类衍生物及其制备方法和用途
GB0905955D0 (en)	2009-04-06	2009-05-20	Respivert Ltd	Novel compounds
GB0921730D0 (en)	2009-12-11	2010-01-27	Respivert Ltd	Method of treatment
GB0921731D0 (en) *	2009-12-11	2010-01-27	Respivert Ltd	Theraputic uses
EP2738162B1 (en)	2010-03-15	2018-01-03	Ube Industries, Ltd.	Method for producing amide compound
GB201005589D0 (en)	2010-04-01	2010-05-19	Respivert Ltd	Novel compounds
JP5787977B2 (ja)	2010-04-08	2015-09-30	レスピバート・リミテツド	Ｐ３８ｍａｐキナーゼ阻害剤
US9260410B2 (en)	2010-04-08	2016-02-16	Respivert Ltd.	P38 MAP kinase inhibitors
WO2011153553A2 (en)	2010-06-04	2011-12-08	The Regents Of The University Of California	Methods and compositions for kinase inhibition
WO2011158044A2 (en)	2010-06-17	2011-12-22	Respivert Limited	Respiratory formulations and compounds for use therein
GB201010196D0 (en)	2010-06-17	2010-07-21	Respivert Ltd	Methods
GB201010193D0 (en)	2010-06-17	2010-07-21	Respivert Ltd	Medicinal use
EP2763984B1 (en)	2011-10-03	2016-04-20	Respivert Limited	1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 map kinase inhibitors
EP2578582A1 (en)	2011-10-03	2013-04-10	Respivert Limited	1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors
GB201214750D0 (en)	2012-08-17	2012-10-03	Respivert Ltd	Compounds
GB201215357D0 (en)	2012-08-29	2012-10-10	Respivert Ltd	Compounds
WO2014033447A2 (en)	2012-08-29	2014-03-06	Respivert Limited	Kinase inhibitors
EP2890701B1 (en)	2012-08-29	2017-03-29	Respivert Limited	Kinase inhibitors
US20150210722A1 (en)	2012-08-29	2015-07-30	Respivert Limited	Kinase inhibitors
WO2014076484A1 (en)	2012-11-16	2014-05-22	Respivert Limited	Kinase inhibitors
US20160016934A1 (en)	2013-03-14	2016-01-21	Respivert Limited	Kinase inhibitors
US9771353B2 (en)	2013-04-02	2017-09-26	Topivert Pharma Limited	Kinase inhibitors based upon N-alkyl pyrazoles
BR112015024678B1 (pt)	2013-04-02	2023-02-23	Oxular Acquisitions Limited	Composto inibidor da cinase, formulação farmacêutica que compreende o mesmo, seus usos, processo para sua preparação e intermediários
US10284974B2 (en)	2013-07-10	2019-05-07	Starkey Laboratories, Inc.	Acoustically transparent barrier layer to seal audio transducers
TWI664967B (zh)	2014-02-14	2019-07-11	英商瑞斯比維特有限公司	新穎化合物（一）
MA40775A (fr)	2014-10-01	2017-08-08	Respivert Ltd	Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38

2012
- 2012-10-03 EP EP12772383.1A patent/EP2763984B1/en active Active
- 2012-10-03 CA CA2846222A patent/CA2846222C/en active Active
- 2012-10-03 CN CN201280048821.1A patent/CN103917536B/zh active Active
- 2012-10-03 EA EA201490730A patent/EA023650B1/ru unknown
- 2012-10-03 AU AU2012320300A patent/AU2012320300C1/en active Active
- 2012-10-03 PT PT127723831T patent/PT2763984T/pt unknown
- 2012-10-03 KR KR1020197018435A patent/KR102057058B1/ko active Active
- 2012-10-03 MX MX2014004018A patent/MX342168B/es active IP Right Grant
- 2012-10-03 PE PE2014000468A patent/PE20142355A1/es active IP Right Grant
- 2012-10-03 WO PCT/GB2012/052445 patent/WO2013050757A1/en not_active Ceased
- 2012-10-03 PH PH1/2014/500547A patent/PH12014500547A1/en unknown
- 2012-10-03 BR BR112014007694-4A patent/BR112014007694B1/pt active IP Right Grant
- 2012-10-03 MY MYPI2014700788A patent/MY167798A/en unknown
- 2012-10-03 ES ES12772383.1T patent/ES2583853T3/es active Active
- 2012-10-03 PL PL12772383.1T patent/PL2763984T3/pl unknown
- 2012-10-03 SG SG11201400226UA patent/SG11201400226UA/en unknown
- 2012-10-03 KR KR1020147007831A patent/KR101995274B1/ko active Active
- 2012-10-03 JP JP2014532482A patent/JP2014528404A/ja active Pending
- 2012-10-03 US US14/349,345 patent/US9108950B2/en active Active
2014
- 2014-02-18 IL IL231025A patent/IL231025A/en active IP Right Grant
- 2014-03-21 CO CO14062064A patent/CO6910202A2/es unknown
- 2014-03-26 GT GT201400054A patent/GT201400054A/es unknown
- 2014-03-27 NI NI201400027A patent/NI201400027A/es unknown
- 2014-04-02 CL CL2014000813A patent/CL2014000813A1/es unknown
- 2014-04-03 EC ECSP14013282 patent/ECSP14013282A/es unknown
- 2014-05-02 ZA ZA2014/03204A patent/ZA201403204B/en unknown
2015
- 2015-04-24 JP JP2015089049A patent/JP5765866B1/ja active Active
- 2015-07-10 US US14/795,957 patent/US9850231B2/en active Active
2017
- 2017-11-14 US US15/812,425 patent/US10266519B2/en active Active
2019
- 2019-02-26 US US16/285,762 patent/US10738032B2/en active Active
2023
- 2023-07-20 US US18/355,710 patent/US20240343711A1/en not_active Abandoned

Also Published As

Publication number	Publication date
ECSP14013282A (es)	2014-05-31
US20180134687A1 (en)	2018-05-17
EA023650B1 (ru)	2016-06-30
KR20190077618A (ko)	2019-07-03
CO6910202A2 (es)	2014-03-31
JP5765866B1 (ja)	2015-08-19
MY167798A (en)	2018-09-26
EP2763984B1 (en)	2016-04-20
US10266519B2 (en)	2019-04-23
WO2013050757A1 (en)	2013-04-11
IL231025A0 (en)	2014-03-31
PL2763984T3 (pl)	2016-10-31
EP2763984A1 (en)	2014-08-13
GT201400054A (es)	2015-02-12
US20160009695A1 (en)	2016-01-14
CN103917536A (zh)	2014-07-09
PT2763984T (pt)	2016-07-25
ES2583853T3 (es)	2016-09-22
US20240343711A1 (en)	2024-10-17
NI201400027A (es)	2015-12-11
HK1199642A1 (zh)	2015-07-10
US9108950B2 (en)	2015-08-18
AU2012320300B2 (en)	2016-09-15
CA2846222C (en)	2020-07-07
KR101995274B1 (ko)	2019-07-02
US20140249169A1 (en)	2014-09-04
SG11201400226UA (en)	2014-09-26
KR102057058B1 (ko)	2019-12-18
JP2015155445A (ja)	2015-08-27
MX2014004018A (es)	2014-05-12
CN103917536B (zh)	2016-07-06
PE20142355A1 (es)	2015-01-10
PH12014500547A1 (en)	2014-04-21
CA2846222A1 (en)	2013-04-11
BR112014007694B1 (pt)	2022-09-27
IL231025A (en)	2016-11-30
NZ621440A (en)	2015-02-27
AU2012320300A1 (en)	2014-03-06
AU2012320300C1 (en)	2017-06-01
ZA201403204B (en)	2016-01-27
US20190185458A1 (en)	2019-06-20
US9850231B2 (en)	2017-12-26
US10738032B2 (en)	2020-08-11
EA201490730A1 (ru)	2014-07-30
BR112014007694A2 (pt)	2017-04-18
MX342168B (es)	2016-09-15
KR20140074908A (ko)	2014-06-18
JP2014528404A (ja)	2014-10-27

Publication	Publication Date	Title
CL2014000813A1 (es)	2014-07-25	El compuesto 1-pirazolil-3-(4-((2-anilinopirimidin-4-il)oxi)naftalen-1-il)urea o sus sales, inhibidor de proteinas cinasas actividas por mitogeno p38; forma sólida cristalina; composicion farmaceutica; combinacion farmaceutica; y su uso en asma, fibrosis quistica, rinitis alergica, psoriasis, entre otras
CR9832A (es)	2008-06-18	Compuestos de pirimidina amida como inhibidores de pgds
CL2013003281A1 (es)	2014-07-25	Compuesto n-(2-{2-dimetilaminoetil-metilamino}-4-metoxi-5-{[4-(1-metilindol-3-il)pirimidin-2-il]amino}fenil)prop-2-enamida y sus sales; composición farmacéutica que los comprende; uso en el tratamiento del cáncer
CL2008000911A1 (es)	2008-10-03	Compuestos derivados de pirimidina, inhibidores de prostaglandina d2; composicion farmaceutica; y uso para tratar un trastorno alergico o inflamatorio tal como rinitis alergica, asma y epoc.
CL2014002386A1 (es)	2015-02-27	Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
DK2327694T3 (da)	2013-10-28	Substituerede 4-aminopicolinsyrer og deres anvendelse som herbicider
BRPI0822104A2 (pt)	2014-10-07	Composições antimicrobianas e métodos para o uso das mesmas
HUE055618T2 (hu)	2021-12-28	2-amino-N-(piperidin-1-il-piridin-3-il)-pirazolo-[1,5-alfa]-pirimidin-3-karboxamid, mint atr-kináz inhibítoraként használható vegyület
BR112013016299A2 (pt)	2016-10-04	artigo abrasivo; e método para formar o mesmo
CL2008001818A1 (es)	2009-03-06	Ácido {4,6-bis(dimetilamino)-2-(4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il}acético amorfo y sus formas cristalinas i y ii; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.
CL2007003187A1 (es)	2008-03-07	Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
BRPI1007937A2 (pt)	2015-09-01	"uso de inibidores de succinato desidrogenase para controlar infecções primárias por oídios"
CL2012003722A1 (es)	2014-03-21	Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2013001723A1 (es)	2013-12-27	Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina; metodos de preparacion; composicion farmaceutica; y el uso en el tratamiento de los trastornos mediados por la cinasa de linfoma anaplasico.
SV2009002861A (es)	2009-02-23	Compuestos de pirimidina amida como inhibidores de pgds
DK2254908T3 (da)	2013-03-04	Kosmetiske eller farmaceutiske sammensætninger omfattende metalloproteinasehæmmere
DK2139892T3 (da)	2011-12-12	Substituerede pyrimidodiazepiner nyttige som PLK1-inhibitorer
BRPI0811871A2 (pt)	2014-12-30	Composições agroquímicas ácidas bioativas e uso das mesmas
CL2011001977A1 (es)	2011-11-18	Compuestos derivados de triazolopiridina, inhibidores de proteinas cinasas activadas por mitogeno p38; composicion farmaceutica; y su uso para el tratamiento de neumonia eosinofilica cronica, asma, enfermedad pulmonar obstructiva cronica y sindrome de angustia respiratoria en adultos, entre otras enfermedades.
BRPI0810863A2 (pt)	2014-10-07	Uso de hidrolisados de proteína para estabilizar formulações de detergente de metaloprotease.
CL2013001947A1 (es)	2014-05-23	Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2007003389A1 (es)	2008-06-27	Formas cristalinas de sales de acido zoledronico; composicion farmaceutica; y uso en el tratamiento del cancer.
BR112014011400A2 (pt)	2017-05-02	inibidores de nadph oxidase 4 e seus usos
AR067328A1 (es)	2009-10-07	Formas amorfas estabilizadas de mesilato de imatinib
CL2008001817A1 (es)	2009-03-13	Sales piperazina, benzatina y colina en forma cristalina del acido {4,6-bis(dimetilamino-2-)4-(4-(trifluorometil)benzamido)bencil)pirimidin-5-il)acético; proceso de preparación; composición farmacéutica; y uso en el tratamiento de enfermedades inflamatorias tales como asma, rinitis alérgica, crohn, entre otras.